Teslexivir

N/A

Report date: 2023/07/01 20:00:34

NME

Base Information

Drug NameTeslexivir

Drug Alias NameAP-611BTA-074AP-611074

ClassificationSmall molecules > Heterocyclic drugs

Mechanisms of ActionVirus replication inhibitorsHuman papillomavirus Replication protein E1 inhibitorsHuman papillomavirus regulatory protein E2 inhibitors

TargetsHuman papillomavirus Replication protein E1Human papillomavirus regulatory protein E2

Therapy Area/IndicationsPapillomavirus InfectionsCondylomata Acuminata

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritorySerbiaEcuadorArgentina +[5]

CombinationsNo

Global Highest StatusPending (Phase 2 Clinical)

Highest Status in ChinaN/A

Originator CompaniesAviragen Therapeutics Inc

China Registration ClassN/A

Develop Information

Active CompaniesN/A

Inactive CompaniesAnaconda Pharma Vaxart Inc

Active IndicationsN/A

Inactive IndicationsPapillomavirus InfectionsCondylomata Acuminata

Other Information

ATC CodeN/A